These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 20727252)

  • 1. Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.
    Cherner M; Bousman C; Everall I; Barron D; Letendre S; Vaida F; Atkinson JH; Heaton R; Grant I;
    J Int Neuropsychol Soc; 2010 Sep; 16(5):890-901. PubMed ID: 20727252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methamphetamine use parameters do not predict neuropsychological impairment in currently abstinent dependent adults.
    Cherner M; Suarez P; Casey C; Deiss R; Letendre S; Marcotte T; Vaida F; Atkinson JH; Grant I; Heaton RK;
    Drug Alcohol Depend; 2010 Jan; 106(2-3):154-63. PubMed ID: 19815352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced CYP2D6 activity is a negative risk factor for methamphetamine dependence.
    Otani K; Ujike H; Sakai A; Okahisa Y; Kotaka T; Inada T; Harano M; Komiyama T; Hori T; Yamada M; Sekine Y; Iwata N; Iyo M; Sora I; Ozaki N; Kuroda S
    Neurosci Lett; 2008 Mar; 434(1):88-92. PubMed ID: 18280655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings.
    Gupta S; Bousman CA; Chana G; Cherner M; Heaton RK; Deutsch R; Ellis RJ; Grant I; Everall IP
    J Neurovirol; 2011 Jun; 17(3):239-47. PubMed ID: 21491142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in CYP2D6 may predict methamphetamine related heart failure.
    Sutter ME; Gaedigk A; Albertson TE; Southard J; Owen KP; Mills LD; Diercks DB
    Clin Toxicol (Phila); 2013 Aug; 51(7):540-4. PubMed ID: 23855716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 genotype may moderate measures of brain structure in methamphetamine users.
    Dean AC; Nurmi EL; Morales AM; Cho AK; Seaman LC; London ED
    Addict Biol; 2021 May; 26(3):e12950. PubMed ID: 32767519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure.
    Gonzalez R; Rippeth JD; Carey CL; Heaton RK; Moore DJ; Schweinsburg BC; Cherner M; Grant I
    Drug Alcohol Depend; 2004 Nov; 76(2):181-90. PubMed ID: 15488342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence.
    Moore DJ; Blackstone K; Woods SP; Ellis RJ; Atkinson JH; Heaton RK; Grant I;
    AIDS Care; 2012; 24(12):1504-13. PubMed ID: 22530794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methamphetamine Exposure Combined with HIV-1 Disease or gp120 Expression: Comparison of Learning and Executive Functions in Humans and Mice.
    Kesby JP; Heaton RK; Young JW; Umlauf A; Woods SP; Letendre SL; Markou A; Grant I; Semenova S
    Neuropsychopharmacology; 2015 Jul; 40(8):1899-909. PubMed ID: 25652249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons.
    Rippeth JD; Heaton RK; Carey CL; Marcotte TD; Moore DJ; Gonzalez R; Wolfson T; Grant I;
    J Int Neuropsychol Soc; 2004 Jan; 10(1):1-14. PubMed ID: 14751002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users.
    Chen CK; Lin SK; Chen YC; Huang MC; Chen TT; Ree SC; Wang LJ
    Drug Alcohol Depend; 2015 Mar; 148():158-64. PubMed ID: 25601645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychological deficits in adolescent methamphetamine abusers.
    King G; Alicata D; Cloak C; Chang L
    Psychopharmacology (Berl); 2010 Oct; 212(2):243-9. PubMed ID: 20640405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
    Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
    Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of amphetamine, methamphetamine, and hydroxyamphetamine derivatives in urine by gas chromatography-mass spectrometry and its relation to CYP2D6 phenotype of drug users.
    Miranda-G E; Sordo M; Salazar AM; Contreras C; Bautista L; Rojas García AE; Ostrosky-Wegman P
    J Anal Toxicol; 2007; 31(1):31-6. PubMed ID: 17389081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence.
    Kalechstein AD; Newton TF; Green M
    J Neuropsychiatry Clin Neurosci; 2003; 15(2):215-20. PubMed ID: 12724464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis use may attenuate neurocognitive performance deficits resulting from methamphetamine use disorder.
    Rogers JM; Grant I; Marcondes MCG; Morgan EE; Cherner M; Ellis RJ; Letendre SL; Heaton RK; Iudicello JE
    J Int Neuropsychol Soc; 2024 Jan; 30(1):84-93. PubMed ID: 37553288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users.
    Chana G; Everall IP; Crews L; Langford D; Adame A; Grant I; Cherner M; Lazzaretto D; Heaton R; Ellis R; Masliah E;
    Neurology; 2006 Oct; 67(8):1486-9. PubMed ID: 17060582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytochrome P450 polymorphism and postoperative cognitive dysfunction.
    Steinmetz J; Jespersgaard C; Dalhoff K; Hedley P; Abildstrøm H; Christiansen M; Rasmussen LS;
    Minerva Anestesiol; 2012 Mar; 78(3):303-9. PubMed ID: 21971440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.